April 23rd 2024
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Polyp Burden Drops With Sulindac/Erlotinib Combo in FAP
February 15th 2018Patients with familial adenomatous polyposis have an increased risk for colorectal polyps and cancer; however, treatment with a combination of sulindac and erlotinib reduced their colorectal polyp burden by more than two thirds.
New Study Suggests MYO5B As a Prognostic Marker for Colorectal Cancer
January 30th 2018Investigators found a methylation-independent loss of MYO5B expression in CRC that matched disease progression, which indicates that the use of MYO5B alone or in combination with its adapter protein RAB8A is a prognostic marker for the disease.
No Benefit With Bevacizumab Maintenance Therapy for Metastatic CRC During Chemo-Free Intervals
January 25th 2018Adding bevacizumab maintenance therapy failed to improve outcomes compared with no treatment when administered during chemotherapy-free intervals to patients with metastatic colorectal cancer after induction chemotherapy.
Nivolumab Plus Ipilimumab Offers Improved Survival Outcomes in Certain Metastatic CRC Patients
January 23rd 2018Patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer who received nivolumab along with ipilimumab had high response rates and improved survival outcomes compared with those who received nivolumab alone.
Woman With Rare Cause of Rectal Bleeding
January 15th 2018A 56-year-old Caucasian woman presented to her primary care physician with a 3-month history of intermittent bright red rectal blood with defecation. At her initial visit, a digital rectal examination, anoscopy, and a pelvic examination with DNA testing for high-risk HPV were performed; all results were negative. She was referred for a colonoscopy, which revealed an abnormal area with a 3 × 4–cm mass in the rectum at a distance of 10 cm from the anal verge.
Smoking Status Correlates With Prognosis Following CRC Diagnosis
December 17th 2017A large meta-analysis found that current and former smoking status was associated with poorer colorectal cancer prognosis compared with never smoking, and that smoking cessation may improve survival over those who continue to smoke.
Aprepitant Warrants More Study for CINV in Patients on FOLFOX for CRC
November 16th 2017Aprepitant plus palonosetron and dexamethasone showed early promise for preventing chemotherapy-induced nausea and vomiting among patients with colorectal cancer who are undergoing FOLFOX chemotherapy, according to results of a small pilot study.
High HER3 Expression in Advanced CRC Related to Anti-EGFR Activity
October 30th 2017HER3 messenger RNA expression may serve as a biomarker for patients with RAS wild type colorectal cancer who will benefit from treatment with the anti-EGFR therapy panitumumab, according to the results of a new study.
Nonoperative Management of Rectal Cancer: A Modern Perspective
In this article, we provide a summary of nonoperative management of locally advanced rectal cancer in the modern era. Our focus is on technical details of tumor response and patient assessment after chemoradiotherapy, as well as a review of existing clinical data.